Janus Henderson Group PLC Has $198.81 Million Stock Position in Apogee Therapeutics Inc. $APGE

Janus Henderson Group PLC grew its stake in Apogee Therapeutics Inc. (NASDAQ:APGE) by 14.4% during the 1st quarter, HoldingsChannel reports. The firm owned 2,360,596 shares of the company’s stock after acquiring an additional 297,992 shares during the quarter. Janus Henderson Group PLC’s holdings in Apogee Therapeutics were worth $198,809,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Commonwealth Equity Services LLC lifted its position in shares of Apogee Therapeutics by 2.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock worth $540,000 after buying an additional 152 shares during the period. Stifel Financial Corp grew its position in Apogee Therapeutics by 3.5% in the fourth quarter. Stifel Financial Corp now owns 5,214 shares of the company’s stock valued at $394,000 after acquiring an additional 175 shares during the period. EverSource Wealth Advisors LLC raised its stake in Apogee Therapeutics by 61.7% during the first quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company’s stock worth $54,000 after acquiring an additional 246 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Apogee Therapeutics during the fourth quarter valued at $25,000. Finally, Comerica Bank lifted its holdings in shares of Apogee Therapeutics by 1.0% during the fourth quarter. Comerica Bank now owns 35,872 shares of the company’s stock valued at $2,708,000 after acquiring an additional 338 shares during the period. 79.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on APGE shares. Deutsche Bank Aktiengesellschaft downgraded shares of Apogee Therapeutics from a “buy” rating to a “hold” rating and lifted their price target for the company from $116.00 to $135.00 in a report on Monday, June 22nd. BTIG Research reaffirmed a “buy” rating and set a $137.00 price objective on shares of Apogee Therapeutics in a research note on Wednesday, May 27th. Rothschild & Co Redburn initiated coverage on shares of Apogee Therapeutics in a report on Friday, May 1st. They set a “buy” rating and a $140.00 price objective for the company. Stifel Nicolaus reiterated a “hold” rating and issued a $135.00 target price (up from $133.00) on shares of Apogee Therapeutics in a research note on Wednesday, June 24th. Finally, Guggenheim downgraded Apogee Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Apogee Therapeutics presently has an average rating of “Hold” and a consensus target price of $121.25.

Insider Buying and Selling

In related news, insider Carl Dambkowski sold 26,400 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $132.60, for a total value of $3,500,640.00. Following the completion of the sale, the insider owned 179,248 shares of the company’s stock, valued at $23,768,284.80. This trade represents a 12.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 80,000 shares of Apogee Therapeutics stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $132.54, for a total value of $10,603,200.00. Following the completion of the sale, the chief executive officer directly owned 1,015,987 shares of the company’s stock, valued at $134,658,916.98. This trade represents a 7.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 182,900 shares of company stock worth $21,711,585 over the last quarter. 24.30% of the stock is owned by company insiders.

Apogee Therapeutics Stock Performance

Shares of NASDAQ:APGE opened at $134.30 on Friday. The business has a fifty day moving average of $112.89 and a 200-day moving average of $89.67. Apogee Therapeutics Inc. has a twelve month low of $34.34 and a twelve month high of $134.46. The firm has a market cap of $8.31 billion, a PE ratio of -31.02 and a beta of 0.32.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.01. On average, analysts anticipate that Apogee Therapeutics Inc. will post -4.45 EPS for the current fiscal year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.